# EDGAR Filing Document

**Accession Number:** 0000818479
**File Stem:** 0000818479-25-000152
**Filing Date:** 2025-8
**Character Count:** 43896
**Document Hash:** 887235a86aaed19690a947f71cceb773
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000818479-25-000152.hdr.sgml**: 20250807

**ACCESSION NUMBER**: 0000818479-25-000152

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250807

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250807

**DATE AS OF CHANGE**: 20250807

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DENTSPLY SIRONA Inc.
- **CENTRAL INDEX KEY:** 0000818479
- **STANDARD INDUSTRIAL CLASSIFICATION:** DENTAL EQUIPMENT & SUPPLIES [3843]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 391434669
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-16211
- **FILM NUMBER:** 251191565

**BUSINESS ADDRESS:**
- **STREET 1:** 13320 BALLANTYNE CORPORATE PLACE
- **CITY:** CHARLOTTE
- **STATE:** NC
- **ZIP:** 28277-3607
- **BUSINESS PHONE:** 844-546-3722

**MAIL ADDRESS:**
- **STREET 1:** 13320 BALLANTYNE CORPORATE PLACE
- **CITY:** CHARLOTTE
- **STATE:** NC
- **ZIP:** 28277-3607

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DENTSPLY INTERNATIONAL INC /DE/
- **DATE OF NAME CHANGE:** 19930630

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GENDEX CORP
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'? xray-20250807

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**<u>August 7, 2025</u>**

Date of Report (date of earliest event reported)

**<u>DENTSPLY SIRONA Inc.</u>**

(Exact name of registrant as specified in its charter)

---

| | | | |
|:---|:---|:---|:---|
| **Delaware** | **0-16211** | **0-16211** | **39-1434669** |
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (Commission File Number) | (I.R.S. Employer Identification No.) |
| **13320 Ballantyne Corporate Place,** | **Charlotte** | **North Carolina** | **28277-3607** |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Zip Code) |

---

**(844) 848-0137** 

Registrant's telephone number, including area code

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | **XRAY** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

□

------

**Item 2.02 &nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition**

On August 7, 2025, DENTSPLY SIRONA Inc. (the "Company") issued a press release regarding the Company's financial results for its second fiscal quarter ended June 30, 2025. A copy of the Company's press release is furnished as Exhibit 99.1.

The information contained in this Current Report on Form 8-K pursuant to Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 &nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits**

(d) Exhibits:

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Description</u>** |
| <u>[99.1](dentsply8kq22025ex991.htm)</u> | DENTSPLY SIRONA Inc. Press release issued August 7, 2025, as referenced in Item 2.02 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL Document) |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;DENTSPLY SIRONA Inc.

---

| | |
|:---|:---|
| By: | */s/ Matthew E. Garth* |
|  | Matthew E. Garth |
|  | Executive Vice President and |
|  | Chief Financial Officer |

---

Date: August 7, 2025

## Exhibit 99.1

![greylogoinjpg.jpg](greylogoinjpg.jpg)

**Dentsply Sirona Reports Second Quarter 2025 Results**

&nbsp;&nbsp;&nbsp;&nbsp;**• Net sales of $936 million decreased (4.9%), decreased (6.7%) in constant currency including a (3.2%) Byte sales impact**

&nbsp;&nbsp;&nbsp;&nbsp;**• GAAP gross margin of 52.4%, GAAP net loss per share of ($0.22)**

&nbsp;&nbsp;&nbsp;&nbsp;**• Adjusted gross margin of 55.9%, adjusted EBITDA margin of 21.1%, adjusted EPS of $0.52**

&nbsp;&nbsp;&nbsp;&nbsp;**• Executed $550 million debt offering**

&nbsp;&nbsp;&nbsp;&nbsp;**• Reaffirmed FY25 outlook**

&nbsp;&nbsp;&nbsp;&nbsp;**• Leadership transition with Dan Scavilla appointed CEO effective August 1, 2025 and Matt Garth appointed CFO effective May 30, 2025**

**Charlotte, N.C., August 7, 2025 -** DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the second quarter of 2025.

Second quarter net sales of $936 million decreased (4.9%) (decreased (6.7%) in constant currency) compared to the second quarter of 2024. Foreign currency changes positively impacted second quarter 2025 net sales by approximately $18 million. Net loss attributable to Dentsply Sirona was ($45) million, or ($0.22) per share, compared to a net loss of ($4) million, or ($0.02) per share in the second quarter of 2024. Non-cash charges for the impairment of goodwill and other intangible assets were ($214) million net of tax, or ($1.07) per share in the second quarter of 2025, versus no impairment charges in the second quarter of 2024. Adjusted earnings per diluted share were $0.52, compared to $0.49 in the second quarter of 2024. A reconciliation of Non-GAAP measures (including constant currency, adjusted EBITDA and margin, adjusted EPS, adjusted free cash flow conversion, and segment adjusted operating income) to GAAP measures is provided below.

"I see tremendous opportunity at Dentsply Sirona and I am looking forward to digging in with the team to increase our customer-centric focus and to direct investments in areas that will generate sustainable growth," said Dan Scavilla, Chief Executive Officer. "I'm confident that these efforts will strengthen Dentsply Sirona as a clear industry leader."

"While top-line results were down in the quarter, we were pleased to continue to deliver margin expansion," said Matt Garth, Chief Financial Officer. "We increased our financial flexibility, drove adjusted EPS growth and are actively focused on enhancing cash flow generation to support the long-term profitable growth of the Company. As we move forward, we plan to advance our initiatives, remain disciplined in our capital allocation, and deliver sustainable value for our shareholders."

**<u>Q2 2025 Summary Results (GAAP)</u>**

---

| | | | |
|:---|:---|:---|:---|
| **(in millions, except per share amount and percentages)** | **Q2 25** | **Q2 24** | **YoY** |
| Net Sales | $936 | $984 | *(4.9%)* |
| Gross Profit | $490 | $511 | *(4.0%)* |
| Gross Margin | 52.4% | 51.9% |  |
| Net Income Attributable to Dentsply Sirona | ($45) | ($4) | *NM* |
| Diluted Earnings Per Share | ($0.22) | ($0.02) | *NM* |

---

------

**<u>Q2 2025 Summary Results (Non-GAAP)</u>**<sup>[1]</sup>

---

| | | | |
|:---|:---|:---|:---|
| **(in millions, except per share amount and percentages)** | **Q2 25** | **Q2 24** | **YoY** |
| Net Sales | $936 | $984 | *(4.9%)* |
| *Constant Currency* |  |  | *(6.7%)* |
| Adjusted Gross Profit | $523 | $544 | *(4.0%)* |
| *Adjusted Gross Margin* | *55.9%* | *55.3%* |  |
| Adjusted EBITDA | $197 | $173 | *14.6%* |
| *Adjusted EBITDA Margin* | *21.1%* | *17.5%* |  |
| Adjusted EPS | $0.52 | $0.49 | *6.6%* |

---

<sup></sup>NM - not meaningful

Percentages are based on actual values and may not reconcile due to rounding.<sup>[1]</sup> Constant currency, adjusted gross profit and margin, adjusted EBITDA and margin, and adjusted EPS are Non-GAAP financial measures which exclude certain items. Please refer to "Non-GAAP Financial Measures" below for a description of these measures and to the tables at the end of this release for a reconciliation between GAAP and Non-GAAP measures.

**<u>Q2 2025 Segment Results</u>**

---

| | | | |
|:---|:---|:---|:---|
| | **Net Sales Change vs. Prior year** | **Net Sales Change vs. Prior year** | **Net Sales Change vs. Prior year** |
| | **Reported** | **Foreign Exchange Impact** | **Constant Currency** |
| Connected Technology Solutions | *(3.8%)* | *2.1%* | *(5.9%)* |
| Essential Dental Solutions | *2.9%* | *1.8%* | *1.1%* |
| Orthodontic and Implant Solutions | *(18.1%)* | *1.3%* | *(19.4%)* |
| Wellspect Healthcare | *1.2%* | *3.7%* | *(2.5%)* |
| Total | *(4.9%)* | *1.8%* | *(6.7%)* |

---

**<u>Q2 2025 Geographic Results</u>**

---

| | | | |
|:---|:---|:---|:---|
| | **Net Sales Change vs. Prior Year** | **Net Sales Change vs. Prior Year** | **Net Sales Change vs. Prior Year** |
| | **Reported** | **Foreign Exchange Impact** | **Constant Currency** |
| United States | *(18.3%)* | *—%* | *(18.3%)* |
| Europe | *4.3%* | *4.7%* | *(0.4%)* |
| Rest of World | *0.5%* | *—%* | *0.5%* |
| Total | *(4.9%)* | *1.8%* | *(6.7%)* |

---

**<u>Cash Flow and Liquidity</u>**

Operating cash flow in the second quarter of 2025 was $48 million, compared to $208 million in the second quarter of 2024; the decrease was primarily due to unfavorable working capital and the receipt of a foreign tax refund in the prior year quarter. In the second quarter of 2025, the Company paid $32 million in dividends resulting in a total of $64 million returned to stockholders in the first six months of 2025. On June, 12, 2025, the Company issued $550 million aggregate principal amount of 8.375% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2055 through a public offering, the proceeds of which were used to repay outstanding amounts under the Company's bridge loan facility and for general corporate purposes. The Company had $359 million of cash and cash equivalents as of June 30, 2025. On July 1, 2025, the Company entered into a series of interest rate swap contracts to manage interest rate risk on long-term debt instruments.

**<u>Goodwill and Indefinite-Lived Intangible Asset Impairment</u>**

In the second quarter of 2025, the Company recorded a non-cash charge for the impairment of goodwill and other indefinite-lived intangible assets of ($214) million net of tax within the Orthodontic and Implant Solutions and Connected Technology Solutions segments. These impairments were

------

driven by the impacts from tariffs and lower volumes in implants and prosthetics and equipment, due partly to competitive pressures.

**<u>2025 Outlook</u>**

The Company is maintaining its 2025 outlook for net sales of $3.60 billion to $3.70 billion, down (4.0%) to (2.0%) on a constant currency basis, and adjusted EPS in the range of $1.80 to $2.00. This outlook reflects the current state of tariffs and trade policy.

Other 2025 outlook assumptions are included in the second quarter 2025 earnings presentation posted on the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. The Company does not provide forward-looking estimates on a GAAP basis as certain information, which may include, but is not limited to, restructuring charges, transformation-related costs, impairment charges, certain tax adjustments, and other significant items, is not available without unreasonable effort and cannot be reasonably estimated. The exact amounts of these charges or credits are not currently determinable but may be significant.

**<u>Quarterly Cash Dividend</u>**

On July 31, 2025, the Company's Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on October 10, 2025, to holders of record as of September 26, 2025.

**Conference Call/Webcast Information**

Dentsply Sirona's management team will host an investor conference call and live webcast on August 7th, 2025, at 8:30 am ET. The live webcast and a presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com.

For those planning to participate on the call, please register at https://register-conf.media-server.com/register/BI53ec0a63538f4269bf74d4ce11a882e4. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call.

**About Dentsply Sirona**

Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering, including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona's innovative products provide, high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona's headquarters is located in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

**Contact Information:**

Investors:

Andrea Daley

Vice President, Investor Relations

+1-704-591-8631

InvestorRelations@dentsplysirona.com

Press:

Marion Par-Weixlberger

Vice President, Public Relations & Corporate Communications

+43 676 848414588

marion.par-weixlberger@dentsplysirona.com

------

**<u>Forward-Looking Statements and Associated Risks</u>**

All statements in this Press Release that do not directly and exclusively relate to historical facts constitute "forward-looking statements." Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control, including those described in Part I, Item 1A, "Risk Factors" of the Company's most recent Annual Report on Form 10-K, Part II, Item 1A, "Risk Factors" of the Company's Quarterly Reports on Form 10-Q for any subsequent fiscal quarters, and any updating information or other factors which may be described in the Company's other filings with the Securities and Exchange Commission (the "SEC"). No assurance can be given that any expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Press Release or to reflect the occurrence of unanticipated events. Investors should understand it is not possible to predict or identify all such factors or risks. As such, you should not consider the risks identified in the Company's SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

(in millions, except per share amounts)

(unaudited)

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
| | 2025 | 2024 | 2025 | 2024 |
| Net sales | $936 | $984 | $1815 | $1937 |
| Cost of products sold | 446 | 473 | 859 | 920 |
| Gross profit | 490 | 511 | 956 | 1017 |
| Selling, general, and administrative expenses | 342 | 399 | 700 | 814 |
| Research and development expenses | 37 | 41 | 73 | 83 |
| Goodwill and intangible asset impairments | 235 |  | 235 | 6 |
| Restructuring and other costs | 4 | 21 | 13 | 22 |
| Operating (loss) income | (128) | 50 | (65) | 92 |
| Other income and expenses: |  |  |  |  |
| &nbsp;&nbsp;Interest expense, net | 24 | 17 | 43 | 35 |
| &nbsp;&nbsp;Other expense (income), net | 1 | (1) | 1 | (8) |
| (Loss) income before income taxes | (153) | 34 | (109) | 65 |
| (Benefit) provision for income taxes | (109) | 38 | (84) | 52 |
| Net (loss) income | (44) | (4) | (25) | 13 |
| Less: Net income (loss) attributable to noncontrolling interest | 1 |  |  | (1) |
| Net (loss) income attributable to Dentsply Sirona | $(45) | $(4) | $(25) | $14 |
| (Loss) earnings per common share attributable to Dentsply Sirona: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.22) | $(0.02) | $(0.13) | $0.07 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.22) | $(0.02) | $(0.13) | $0.07 |
| Weighted average common shares outstanding: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | 199.3 | 205.6 | 199.2 | 206.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | 199.3 | 205.6 | 199.2 | 207.3 |

---

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

(in millions, except share and per share amounts)

(unaudited)

---

| | | |
|:---|:---|:---|
| | June 30, 2025 | December 31, 2024 |
| **Assets** |  |  |
| &nbsp;&nbsp;Current Assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $359 | $272 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivable-trade, net | 646 | 556 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | 675 | 564 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 286 | 354 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets | 1966 | 1746 |
| &nbsp;&nbsp;Property, plant, and equipment, net | 840 | 766 |
| &nbsp;&nbsp;Operating lease right-of-use assets, net | 139 | 136 |
| &nbsp;&nbsp;Identifiable intangible assets, net | 1133 | 1207 |
| &nbsp;&nbsp;Goodwill | 1528 | 1597 |
| &nbsp;&nbsp;Other noncurrent assets | 463 | 301 |
| Total Assets | $6069 | $5753 |
| **Liabilities and Equity** |  |  |
| &nbsp;&nbsp;Current Liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $268 | $241 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 672 | 754 |
| &nbsp;&nbsp;&nbsp;&nbsp;Income taxes payable | 42 | 45 |
| &nbsp;&nbsp;&nbsp;&nbsp;Notes payable and current portion of long-term debt | 184 | 549 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Liabilities | 1166 | 1589 |
| &nbsp;&nbsp;Long-term debt | 2218 | 1586 |
| &nbsp;&nbsp;Operating lease liabilities | 92 | 91 |
| &nbsp;&nbsp;Deferred income taxes | 109 | 129 |
| &nbsp;&nbsp;Other noncurrent liabilities | 523 | 415 |
| Total Liabilities | 4108 | 3810 |
| Total Equity | 1961 | 1943 |
| Total Liabilities and Equity | $6069 | $5753 |

---

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

(in millions)

(unaudited)

---

| | | |
|:---|:---|:---|
| | Six Months Ended June 30, | Six Months Ended June 30, |
| | 2025 | 2024 |
| **Cash flows from operating activities:** |  |  |
| Net (loss) income | $(25) | $13 |
| Adjustments to reconcile net loss to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation | 68 | 64 |
| &nbsp;&nbsp;&nbsp;Amortization of intangible assets | 99 | 108 |
| &nbsp;&nbsp;&nbsp;Goodwill asset impairment | 156 |  |
| &nbsp;&nbsp;&nbsp;Indefinite-lived intangible asset impairment | 79 | 6 |
| &nbsp;&nbsp;&nbsp;Deferred income taxes | (136) | (11) |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense | 19 | 23 |
| &nbsp;&nbsp;&nbsp;Other non-cash expense | 19 | 38 |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts and notes receivable-trade, net | (31) | 86 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | (47) | (7) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 26 | 29 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other noncurrent assets | 1 | (6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (10) | (11) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | (35) | (78) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes | (55) | (9) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other noncurrent liabilities | (73) | (12) |
| **Net cash provided by operating activities** | 55 | 233 |
| **Cash flows from investing activities:** |  |  |
| Capital expenditures | (51) | (86) |
| Cash received on derivative contracts | 1 | 1 |
| Cash paid on derivative contracts | (2) | (9) |
| Proceeds from sale of property, plant, and equipment | 1 | 1 |
| **Net cash used in investing activities** | (51) | (93) |
| **Cash flows from financing activities:** |  |  |
| Cash paid for treasury stock |  | (150) |
| (Repayments) proceeds on other short-term borrowings, net | (413) | 43 |
| Proceeds from 364-day bridge loan | 435 |  |
| Repayment of 364-day bridge loan | (435) | 0 |
| Cash dividends paid | (64) | (62) |
| Proceeds from long-term borrowings | 550 |  |
| Repayments on long-term borrowings | (2) | (6) |
| Cash paid for deferred financing costs | (13) |  |
| Other financing activities, net | (3) | (10) |
| **Net cash provided by (used in) financing activities** | 55 | (185) |
| Effect of exchange rate changes on cash and cash equivalents | 28 | (10) |
| Net increase (decrease) in cash and cash equivalents | 87 | (55) |
| Cash and cash equivalents at beginning of period | 272 | 334 |
| Cash and cash equivalents at end of period | $359 | $279 |
| Supplemental disclosures of cash flow information: |  |  |
| &nbsp;&nbsp;&nbsp;Interest paid, net of amounts capitalized | $13 | $44 |
| Non-cash investing activities: |  |  |
| &nbsp;&nbsp;&nbsp;Property, plant and equipment in accounts payable at end of period | $25 | $29 |
| &nbsp;&nbsp;&nbsp;Exchange of inventory for naming and other rights | $14 | $— |

---

------

**<u>Non-GAAP Financial Measures</u>**

In addition to results determined in accordance with U.S. generally accepted accounting principles ("US GAAP"), the Company provides certain measures in this press release, described below, which are not calculated in accordance with US GAAP and therefore represent Non-GAAP financial measures. These Non-GAAP financial measures are used by the Company to measure its performance and may differ from those used by other companies. These Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP.

Management believes that these Non-GAAP financial measures are helpful as they provide a measure of the results of operations, and are frequently used by investors and analysts to evaluate the Company's performance exclusive of certain items that impact the comparability of results from period to period, and which may not be indicative of past or future performance of the Company.

<u>Constant Currency</u>

The Company defines "constant currency" as the reported net sales adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's foreign currency exchange rates.

<u>Adjusted Operating Income and Margin</u>

Adjusted operating income is computed by excluding the following items from operating income (loss) as reported in accordance with US GAAP:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) Business combination-related costs. These adjustments include costs related to consummating and integrating acquired businesses, as well as net gains and losses related to disposed businesses. In addition, this category includes the post-acquisition roll-off of fair value adjustments recorded related to business combinations, except for amortization expense of purchased intangible assets noted below. Although the Company is regularly engaged in activities to find and act on opportunities for strategic growth and enhancement of product offerings, the costs associated with these activities may vary significantly between periods based on the timing, size and complexity of acquisitions and as such may not be indicative of past and future performance of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) Restructuring-related charges and other costs. These adjustments include costs related to the implementation of restructuring initiatives, including but not limited to, severance costs, facility closure costs, and lease and contract termination costs, as well as related professional service costs associated with these restructuring initiatives and global transformation activity. The Company is continually seeking to take actions that could enhance its efficiency; consequently, restructuring charges may recur but are subject to significant fluctuations from period to period due to the varying levels of restructuring activity, and as such may not be indicative of past and future performance of the Company. Other costs include gains and losses on the sale of property, legal settlements, executive separation costs, write-offs of inventory as a result of product rationalization, and changes in accounting principles recorded within the period. This category also includes costs related to investigations and associated legal cases and remediation activities, which primarily include legal, accounting and other professional service fees, as well as turnover and other employee-related costs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) Goodwill and intangible asset impairments. These adjustments include charges related to goodwill and intangible asset impairments.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) Amortization of purchased intangible assets. This adjustment includes the periodic amortization expense related to purchased intangible assets, which are recorded at fair value. Although these costs contribute to revenue generation and will recur in future periods, their amounts are significantly impacted by the timing and size of acquisitions, and as such may not be indicative of the future performance of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) Fair value and credit risk adjustments. These adjustments include the non-cash mark-to-market changes in fair value associated with pension assets and obligations, the credit risk component of hedging instruments, contingent consideration from past acquisitions, and equity-method investments. Although these adjustments are recurring in nature, they are subject to significant fluctuations from period to period due to changes in the underlying assumptions and market conditions. The non-service component of pension expense is a recurring item, however it is subject to significant fluctuations from period to period due to changes in actuarial assumptions, interest rates, plan changes, settlements, curtailments, and other changes in facts and circumstances. As such, these items may not be indicative of past and future performance of the Company.

Adjusted operating margin is calculated by dividing adjusted operating income by net sales.

<u>Adjusted Gross Profit and Margin</u>

Adjusted gross profit is computed by excluding from gross profit the impact of any of the above adjustments that affect either net sales or cost of sales.

Adjusted gross margin is calculated by dividing adjusted gross profit by net sales.

<u>Adjusted Net Income (Loss)</u>

Adjusted net income (loss) consists of net income (loss) as reported in accordance with US GAAP, adjusted to exclude the items identified above, as well as the related income tax impacts of those items. The income tax effect of each pre-tax adjustment was determined based on the tax rate of the jurisdiction in which the related pre-tax adjustment was recorded.

Additionally, net income is adjusted for other tax-related adjustments such as discrete or significant adjustments to valuation allowances and other uncertain tax positions, final settlement of income tax audits, discrete tax items resulting from the implementation of restructuring initiatives, the windfall or shortfall relating to exercise of employee stock-based compensation, any difference between the interim and annual effective tax rate, and adjustments relating to prior periods.

Management believes that these adjustments for certain tax-related matters are helpful to normalize the tax effects of certain discrete or significant items that are irregular or infrequent in timing and may not be indicative of past or future performance of the Company.

<u>Adjusted EBITDA and Margin</u>

In addition to the adjustments described above in arriving at adjusted net income, adjusted EBITDA is computed by further excluding any remaining interest expense, net, income tax expense, depreciation and amortization.

Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by net sales.

<u>Adjusted Earnings (Loss) Per Diluted Share</u>

------

Adjusted earnings (loss) per diluted share (adjusted EPS) is computed by dividing adjusted earnings (loss) attributable to Dentsply Sirona stockholders by the diluted weighted average number of common shares outstanding.

<u>Adjusted Free Cash Flow and Conversion</u>

The Company defines adjusted free cash flow as net cash provided by operating activities minus capital expenditures during the same period, and adjusted free cash flow conversion is defined as adjusted free cash flow divided by adjusted net income (loss). Management believes these Non-GAAP financial measures are important for use in evaluating the Company's financial performance as it measures our ability to efficiently generate cash from our business operations relative to earnings. It should be considered in addition to, rather than as a substitute for, net income (loss) as a measure of our performance or net cash provided by operating activities as a measure of our liquidity.

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

(In millions, except percentages)

(unaudited)

A reconciliation of reported net sales change to change in net sales on a constant currency basis by segment is as follows:

---

| | | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Q2 2025 Change** | **Q2 2025 Change** | **Q2 2025 Change** | **Q2 2025 Change** | **Q2 2025 Change** | **Three Months Ended June 30, 2024** | **Three Months Ended June 30, 2024** | **Three Months Ended June 30, 2024** | **Three Months Ended June 30, 2024** | **Three Months Ended June 30, 2024** |
|<br>(in millions, except percentages) | **Connected Technology Solutions** | **Essential Dental Solutions** | **Orthodontic and Implant Solutions** | **Wellspect Healthcare** | **Total** | **Connected Technology Solutions** | **Essential Dental Solutions** | **Orthodontic and Implant Solutions** | **Wellspect Healthcare** | **Total** | **Connected Technology Solutions** | **Essential Dental Solutions** | **Orthodontic and Implant Solutions** | **Wellspect Healthcare** | **Total** |
| **Net sales** | $243 | $387 | $226 | $80 | $936 | (3.8%) | 2.9% | (18.1%) | 1.2% | (4.9%) | $253 | $375 | $276 | $80 | $984 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange impact |  |  |  |  |  | 2.1% | 1.8% | 1.3% | 3.7% | 1.8% |  |  |  |  |  |
| **Constant currency** |  |  |  |  |  | **(5.9** **%)** | **1.1%** | **(19.4** **%)** | **(2.5** **%)** | **(6.7** **%)** |  |  |  |  |  |

---

Percentages are based on actual values and may not reconcile due to rounding.

A reconciliation of reported net sales change to change in net sales on a constant currency basis by geographic region is as follows:

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Three Months Ended June 30, 2025** | **Q2 2025 Change** | **Q2 2025 Change** | **Q2 2025 Change** | **Q2 2025 Change** | **Three Months Ended June 30, 2024** | **Three Months Ended June 30, 2024** | **Three Months Ended June 30, 2024** | **Three Months Ended June 30, 2024** |
|<br>(in millions, except percentages) | **U.S.** | **Europe** | **ROW** | **Total** | **U.S.** | **Europe** | **ROW** | **Total** | **U.S.** | **Europe** | **ROW** | **Total** |
| **Net sales** | $293 | $404 | $239 | $936 | (18.3%) | 4.3% | 0.5% | (4.9%) | $360 | $387 | $237 | $984 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign exchange impact |  |  |  |  | —% | 4.7% | —% | 1.8% |  |  |  |  |
| **Constant currency** |  |  |  |  | **(18.3** **%)** | **(0.4** **%)** | **0.5%** | **(6.7** **%)** |  |  |  |  |

---

Percentages are based on actual values and may not reconcile due to rounding.

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

(In millions, except percentages)

(unaudited)

The Company's segment adjusted operating income for the three and six months ended June 30, 2025 and 2024 was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Three Months Ended June 30, | Three Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
| (in millions) | 2025 | 2024 | 2025 | 2024 |
| Connected Technology Solutions | $12 | $3 | $19 | $5 |
| Essential Dental Solutions | 151 | 125 | 287 | 240 |
| Orthodontic and Implant Solutions | 45 | 42 | 82 | 84 |
| Wellspect Healthcare | 25 | 24 | 50 | 47 |
| &nbsp;&nbsp;&nbsp;Segment adjusted operating income | 233 | 194 | 438 | 376 |
| **Reconciling items expense (income):** |  |  |  |  |
| &nbsp;&nbsp;All other (a) | 68 | 69 | 155 | 148 |
| &nbsp;&nbsp;&nbsp;Goodwill and intangible asset impairments | 235 |  | 235 | 6 |
| &nbsp;&nbsp;&nbsp;Restructuring and other costs | 4 | 21 | 13 | 22 |
| &nbsp;&nbsp;&nbsp;Interest expense, net | 24 | 17 | 43 | 35 |
| &nbsp;&nbsp;&nbsp;Other expense (income), net | 1 | (1) | 1 | (8) |
| &nbsp;&nbsp;&nbsp;Amortization of intangible assets | 54 | 54 | 99 | 108 |
| &nbsp;&nbsp;&nbsp;Depreciation resulting from the fair value step-up of property, plant, and equipment from business combinations |  |  | 1 |  |
| (Loss) income before income taxes | $(153) | $34 | $(109) | $65 |

---

(a) Includes unassigned corporate headquarters costs.

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

(In millions, except percentages)

(unaudited)

For the three months ended June 30, 2025, a reconciliation of selected items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP items is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| (in millions, except percentages and per share data) | Gross Profit | Operating (loss) income | Net Income Attributable to Dentsply Sirona (a) | Diluted EPS |
| **GAAP** | $490 | $(128) | $(45) | $(0.22) |
| Non-GAAP Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of Purchased Intangible Assets | 32 | 54 | 40 | 0.20 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring-Related Charges and Other Costs |  | 5 | 4 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill and Intangible Asset Impairments |  | 235 | 214 | 1.07 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Business Combination-Related Costs | 1 | 4 | 3 | 0.01 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair Value and Credit Risk Adjustments |  |  | (4) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income Tax-Related Adjustments |  |  | (108) | (0.54) |
| **Adjusted Non-GAAP** | $523 | $170 | $104 | $0.52 |
| GAAP Margin | 52.4% | (13.7%) |  |  |
| Adjusted Non-GAAP Margin | 55.9% | 18.2% |  |  |
| Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share | Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share | Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share | Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share | 199.3 |
| Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share | Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share | Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share | Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share | 199.9 |
| (a) The tax expense on the Non-GAAP adjustments totals $145 million which is inclusive of the $(108) million income tax-related adjustment above.  | (a) The tax expense on the Non-GAAP adjustments totals $145 million which is inclusive of the $(108) million income tax-related adjustment above.  | (a) The tax expense on the Non-GAAP adjustments totals $145 million which is inclusive of the $(108) million income tax-related adjustment above.  | (a) The tax expense on the Non-GAAP adjustments totals $145 million which is inclusive of the $(108) million income tax-related adjustment above.  |  |

---

Percentages are based on actual values and may not reconcile due to rounding.

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

(In millions, except percentages)

(unaudited)

For the three months ended June 30, 2024, a reconciliation of selected items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP items is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| (in millions, except percentages and per share data) | Gross Profit | Operating (loss) income | Net Income Attributable to Dentsply Sirona (a) | Diluted EPS |
| **GAAP** | $511 | $50 | $(4) | $(0.02) |
| Non-GAAP Adjustments: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amortization of Purchased Intangible Assets | 30 | 54 | 40 | 0.19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring-Related Charges and Other Costs | 3 | 35 | 28 | 0.14 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fair Value and Credit Risk Adjustments |  |  | 1 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income Tax-Related Adjustments |  |  | 36 | 0.18 |
| **Adjusted Non-GAAP** | $544 | $139 | $101 | $0.49 |
| GAAP Margin | 51.9% | 5.1% |  |  |
| Adjusted Non-GAAP Margin | 55.3% | 14.2% |  |  |
| Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share | Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share | Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share | Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share | 205.6 |
| Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share | Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share | Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share | Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share | 206.1 |
| (a) The tax expense on the Non-GAAP adjustments totals $(15) million, which is inclusive of the $36 million income tax-related adjustment above. | (a) The tax expense on the Non-GAAP adjustments totals $(15) million, which is inclusive of the $36 million income tax-related adjustment above. | (a) The tax expense on the Non-GAAP adjustments totals $(15) million, which is inclusive of the $36 million income tax-related adjustment above. | (a) The tax expense on the Non-GAAP adjustments totals $(15) million, which is inclusive of the $36 million income tax-related adjustment above. |  |

---

Percentages are based on actual values and may not reconcile due to rounding.

------

**DENTSPLY SIRONA INC. AND SUBSIDIARIES**

(In millions, except percentages)

(unaudited)

A reconciliation of reported net income attributable to Dentsply Sirona to adjusted EBITDA and margin for the three months ended June 30, 2025 and 2024 is as follows:

---

| | | |
|:---|:---|:---|
| | Three Months Ended June 30, | Three Months Ended June 30, |
| (in millions, except percentages) | 2025 | 2024 |
| **Net income attributable to Dentsply Sirona** | $(45) | $(4) |
| &nbsp;&nbsp;Interest expense, net | 24 | 17 |
| &nbsp;&nbsp;Income tax expense | (109) | 38 |
| &nbsp;&nbsp;Depreciation<sup>(1)</sup> | 33 | 32 |
| &nbsp;&nbsp;Amortization of purchased intangible assets | 54 | 54 |
| &nbsp;&nbsp;Restructuring-related charges and other costs | 5 | 35 |
| &nbsp;&nbsp;Goodwill and intangible asset impairments | 235 |  |
| &nbsp;&nbsp;Business combination-related costs and fair value adjustments | 4 |  |
| &nbsp;&nbsp;Fair value and credit risk adjustments | (4) | 1 |
| **Adjusted EBITDA** | $197 | $173 |
| Net sales | $936 | $984 |
| **Adjusted EBITDA margin** | 21.1% | 17.5% |

---

(1) Excludes those depreciation-related amounts which were included as part of the business combination-related adjustments and Restructuring-related charges and other costs.

Percentages are based on actual values and may not reconcile due to rounding.

A reconciliation of adjusted free cash flow conversion for the three months ended June 30, 2025 and 2024 is as follows:

---

| | | |
|:---|:---|:---|
| | Three Months Ended June 30, | Three Months Ended June 30, |
| (in millions, except percentages) | 2025 | 2024 |
| Net cash provided by operating activities | $48 | $208 |
| Capital expenditures | (32) | (52) |
| Adjusted free cash flow | $16 | $156 |
| Adjusted net income | $104 | $101 |
| **Adjusted free cash flow conversion** | 15% | 155% |

---

Percentages are based on actual values and may not reconcile due to rounding.

<br>